Keyword: Tykerb

After an average 44% price cuts, Chinese government will add some blockbuster foreign meds like Celgene's Revlimid to its national insurance scheme.

PRA and Takeda are building a Japan JV, Sun's quarterly profits dropped, ASLAN posted positive top-line phase 2 data for varlitinib.

ASLAN just rolled out positive top-line phase 2 data for its lead drug candidate varlitinib when combined with chemotherapy for the treatment of HER2-positive breast cancer.

As California’s Puma Biotechnology awaits FDA word on its breast cancer drug neratinib, an Advera Health analysis outlines the drug's risks and paints a mixed picture for efficacy versus Roche’s Herceptin and Novartis’ Tykerb.